Upper Limb tDCS in Chronic Stroke Patients (NOURISH)
Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · Nov 1, 2022
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The NOURISH clinical trial is studying a treatment called Transcranial Direct Current Stimulation (tDCS) to see if it can help improve movement in the arms of people who have had a stroke. The trial is looking for participants aged 21 to 80 who have had their first stroke between 6 months and 2 years ago and have some difficulty using their affected arm. This study will involve about 51 participants, who will be divided into three groups. Two groups will receive actual tDCS treatment while the third group will receive a "sham" treatment, which means they will get a very short, non-effective version of the stimulation.
Participants will attend daily sessions for about a month, where they will receive tDCS for 20 minutes along with a standard therapy called GRASP, which focuses on improving arm function. Researchers will assess how well the treatment works by measuring various aspects of arm movement and brain activity before, immediately after, and one month after the treatment. It's important to note that individuals with certain medical conditions, like pregnancy, epilepsy, or major depression, will not be eligible to participate. This trial is currently recruiting participants, and those who join can expect to contribute valuable information that could help improve recovery for stroke patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 21-80 years old;
- • First ever stroke, 6 months to 2 years after stroke onset;
- • ARAT≤42
- Exclusion Criteria:
- • 1. Pregnancy;
- • 2. Any metal implants inside the body that are contraindications of MRI scan;
- • 3. cardiac pacemakers;
- • 4. History of epilepsy;
- • 5. Sensorimotor disturbance due to other causes other than stroke;
- • 6. Claustrophobia;
- • 7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina;
- • 8. Major depression and a history of psychotic disorders;
- • 9. Terminal diagnosis with life expectancy \<=1 year. Any metal implants inside the body that are contraindications of MRI scan;
- • 3. cardiac pacemakers; 4. History of epilepsy; 5. Sensorimotor disturbance due to other causes other than stroke; 6. Claustrophobia; 7. Uncontrolled medical conditions including hypertension, diabetes mellitus and unstable angina; 8. Major depression and a history of psychotic disorders; 9. Terminal diagnosis with life expectancy \<=1 year.
About National University Hospital, Singapore
National University Hospital (NUH) in Singapore is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, NUH emphasizes a multidisciplinary approach, integrating cutting-edge medical research with high-quality patient care. The hospital collaborates with various stakeholders, including academic institutions and industry partners, to explore new therapies and improve treatment outcomes across a wide range of medical disciplines. Committed to ethical standards and patient safety, NUH plays a pivotal role in shaping the future of medicine in Singapore and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Singapore, , Singapore
Patients applied
Trial Officials
Effie Chew, MBBS
Principal Investigator
National University Hospital, Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials